Institutional inflows have strengthened support levels in the $60–$62 range, pointing to resilience against broader healthcare sector volatility. Annual earnings are forecast to grow for the next 3 years. On Dec. 2, Morgan Stanley upgraded the stock to “Overweight” from “Equal Weight” with a price target of $100, up from $83. The firm anticipates that Globus’ AR headset will receive FDA clearance in Q4, highlighting management’s intention to advance navigation with the headset, which is designed to integrate with ExcelsiusHub. The GMED stock price forecast reflects heightened M&A speculation across MedTech, which could indirectly boost valuations in the sector. Analysts note peer acquisition rumors often spill over into similar companies.